Anti-IL23α (Risankizumab), Humanized Antibody

Anti-IL23α (Risankizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of IL-23α. IL-23 is a pro-inflammatory cytokine that is primarily secreted by dendritic cells, monocytes, and macrophages. It is a heterodimeric complex that consists of p19 and p40 subunit. p19 subunit is unique for IL-23 whereas the p40 subunit is shared with IL-12. IL-23 plays an important role in the pathogenesis of inflammatory diseases such as psoriasis. Binding of the antibody to IL-23α prevents the interaction with IL-23 receptor and thereby inhibits inflammatory responses. The original drug received approval from the FDA to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Immunogen Sequence:Human IL23α

Target Alternative Name:655066-01, ABBV-066, BI 655066, P19, SGRF, IL-23, IL23A, IL23P19

Species Reactivities:/

Tag Line:The biosimilar is a humanized monoclonal antibody that targets IL-23α and prevents its association with the IL-23 receptor. This results in inhibition of release of pro-inflammatory chemokines and cytokines

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.